Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Epimmune Enters Agreement For $13.5M Stock Merger With Anosys

May 13, 2003

By Aaron Lorenzo

Epimmune Enters Agreement For $13.5M Stock Merger With Anosys

May 13, 2003

By Aaron Lorenzo

Symyx Spins Off Therapeutics Group, Secures $8M Financing

May 12, 2003

By Aaron Lorenzo

Symyx Spins Off Therapeutics Group, Secures $8M Financing

May 12, 2003

By Aaron Lorenzo

Guilford Licenses Inhibitor Class To Pfizer As Part Of Broad Deal

May 9, 2003

By Aaron Lorenzo

Guilford Pharmaceuticals Inc. is licensing an entire class of potential neurodegenerative disease drugs to Pfizer Inc. for $5 million up front in a deal that could become much more lucrative down the road. (BioWorld Today)

Guilford Licenses Inhibitor Class To Pfizer As Part Of Broad Deal

May 9, 2003

By Aaron Lorenzo

Guilford Pharmaceuticals Inc. is licensing an entire class of potential neurodegenerative disease drugs to Pfizer Inc. for $5 million up front in a deal that could become much more lucrative down the road. (BioWorld Today)

Study Of Memantine In Pain Misses Primary Endpoints

May 8, 2003

By Aaron Lorenzo

Negative trial news Wednesday sent ripples through companies involved in the development of memantine. (BioWorld Today)

Study Of Memantine In Pain Misses Primary Endpoints

May 8, 2003

By Aaron Lorenzo

Negative trial news Wednesday sent ripples through companies involved in the development of memantine. (BioWorld Today)

Employees Return To Genelabs As $8.1 Million Placement Closes

May 6, 2003

By Aaron Lorenzo

AVI Raises $15M Privately From Investors Who Acted In A Hurry

May 6, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.